Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Bausch + Lomb $1.75 billion financing for acquisition of certain Novartis assets
We are advising Bausch + Lomb on the financing
Laekna HK$791 million IPO
We advised Laekna on its IPO and HKEX listing
Centogene strategic collaboration with Lifera
We are advising Centogene on its joint venture with and convertible debt investment by Lifera
Noile-Immune Biotech ¥3.1 billion global IPO
The shares are listed on the Tokyo Stock Exchange
IDEAYA Biosciences $250 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
ATI Physical Therapy $100 million convertibles offering and recapitalization
We advised an ad hoc group of term lenders in connection with the transaction
Editas Medicine $125 million follow-on offering
The stock is listed on the Nasdaq Global Select Market
Cutia Therapeutics HK$412.9 million IPO
We advised Cutia on its IPO and HKEX listing
Tricida chapter 11 liquidation
We advised an ad hoc group of noteholders in connection with Tricida’s chapter 11 proceedings
Akoya Biosciences $50 million follow-on offering
The stock is listed on Nasdaq